Functionally, dual silencing of DLEU1 and ASCC2, in combination with G6PD inhibition, synergistically suppressed the viability of GC cells and tumor growth in vivo, highlighting the therapeutic potential of targeting the DLEU1/ASCC2/G6PD axis. The gene discussed is DLEU1; the disease is gastric cancer.